###### Strengths and limitations of this study

-   The strength of this systematic review is its extensive, unbiased search of various databases without a language restriction.

-   The trial screening and data extraction will be conducted independently by two of the authors.

-   Our systematic review may pertain to the potential incompleteness of the evidence reviewed, including publication and location bias, poor quality of the primary data and poor reporting of results.

Introduction {#s1}
============

Description of the condition {#s1a}
----------------------------

Otitis media with effusion (OME) is characterised by the presence of middle-ear effusion without the signs and symptoms of an acute ear infection and a disease course of months until recovery.[@R1] Otitis media affects nearly every child at least once, and approximately 90% of children experience an episode of OME before reaching school age.[@R5] [@R6] The aetiology of OME is uncertain, but poor clearance due to poor Eustachian tube function, local inflammatory reactions, low-grade infection, allergic reactions and adenoidal infection or hypertrophy have been implicated.[@R7] Many episodes resolve spontaneously within 3 months, but approximately 35--50% of patients with OME experience chronic or recurrent states of this disease. Persistent, symptomatic and untreated OME may lead to major functional limitations such as permanent hearing loss, which may delay language, speech and cognitive development.[@R8] The high prevalence and potential complications of OME cause high socioeconomic consequences, the loss of the caregivers' income and working time and the children\'s time in addition to medical costs. The combined direct and indirect annual cost of OME was US\$4 billion in the USA.[@R4] [@R5]

Description of the intervention {#s1b}
-------------------------------

Antibiotics and steroids have been suggested to provide only a marginal benefit, and antihistamines are not recommended in systematic reviews. Thus, based on the current evidence regarding the efficacy of treatments for OME, the recommendation is to not administer medications but instead follow an observational policy for at least 3 months from its onset.[@R11] The decision to provide surgical treatment is to be considered after 3 months of observation with evaluation of hearing. A review of randomised controlled trials revealed that the insertion of ventilation tubes reduced the proportion of time spent with effusion compared with watchful waiting. However, surgical treatment may lead to adverse effects, such as tympanosclerosis and tympanic membrane abnormalities.[@R14] [@R15]

Currently, many patients who are seeking ways to relieve the symptoms associated with chronic OME or to avoid the side effects of conventional treatment have chosen complementary and alternative medicine (CAM). Herbal medicine, a part of CAM, is the medical utilisation of medicinal plants, minerals and animal parts to prevent or treat clinical conditions.[@R16] According to the survey data, herbal medicine was commonly used to treat respiratory problems, digestive problems, allergies and insomnia. A US survey indicated that 16.4% of patients visiting an internal medicine clinic currently used herbal medicines.[@R17] [@R18]

How the intervention might work {#s1c}
-------------------------------

Many types of herbal medicines are known to have immunomodulatory properties and show anti-inflammatory efficacy in clinical research.[@R19] In experimental research, herbal medicines reduced swelling and prevented endotoxin-induced otitis media through stimulating the mucociliary system for pathogen clearance. Additionally, many types of herbal medicines had anti-inflammatory and antibacterial effects in experiments using an otitis media animal model.[@R22] However, the mechanisms underlying the observed immunomodulatory properties of herbal medicines are currently unclear.

Why it is important to perform this review {#s1d}
------------------------------------------

Notwithstanding the increased use of herbal medicines in the treatment of otitis media, no systematic reviews assessing the intervention of herbal drugs treatment for OME have been conducted to date.[@R16] [@R27] Understanding the efficacy and safety of herbal medicines will allow the appropriate recommendation of an herbal drug treatment for patients.

Objectives {#s1e}
----------

Thus, we propose to undertake a systematic review to assess the safety and efficacy of herbal drugs for the treatment of OME.

Methods {#s2}
=======

Criteria for considering studies for this review {#s2a}
------------------------------------------------

### Types of studies {#s2a1}

Randomised controlled trials (RCTs) and quasi-RCTs (the group allocation was not purely random but rather determined by a factor such as a birth date, a hospital record number or an alternation) will be included. Cluster RCTs, case studies, case series, qualitative studies and uncontrolled trials will be excluded. Trials that do not provide detailed results will also be excluded. Dissertations and abstracts will be included if these contain sufficient details for critical evaluation. No language restriction will be imposed. If we encounter languages other than English, Korean and Chinese, we will either contact the original authors or obtain a translation of the manuscript from professional service.

### Types of participants {#s2a2}

The studies that evaluated patients who had a diagnosis of OME will be included. The diagnostic criteria for OME should be based on the criteria of the American Academy of Pediatrics (AAP) and the American Academy of Otolaryngology and Head and Neck Surgery (AAOHNS).[@R5] We will exclude studies of patients with ventilation tubes present, patients with an anatomical deformity or patients with other chronic immunocompromised states.

### Types of interventions {#s2a3}

We will include those trials using the oral administration of herbal medicine alone or as a combined therapy of the oral administration of herbal medicine with a conventional therapy versus the same conventional therapy. Herbal medicine is defined as a single herb, an individually prescribed herbal formula or herbal products extracted from natural herbs. There is no limitation on the number of herbs used, the dosage, the forms of medication or the duration of the treatment. We will include only the oral administration of the medication.

### Types of outcome measures {#s2a4}

The following outcome measures will be assessed based on analyses of the data obtained in the included trials

#### Primary outcome {#s2b}

Complete resolution of OME (however measured) at 2 or 3 months postrandomisation (resolution in the affected ear in participants with unilateral OME at randomisation and resolution in both ears of those with bilateral OME).

#### Secondary outcomes {#s2c}

1.  Partial or complete resolution of OME at all possible time points

2.  Duration of hearing loss as defined by pure-tone audiometric loss of more than 20 dB

3.  Language and speech development

4.  Cognitive development

5.  Insertion of ventilation tubes

6.  Tympanic membrane sequelae

7.  Reduction of complication of OME

8.  Quality of life

9.  Adverse effects likely to be related to treatment

Search methods for identifying the studies {#s2d}
------------------------------------------

### Electronic searches {#s2d1}

Electronic search will be conducted using MEDLINE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, the Allied and Complementary Medicine Database (AMED) and the Cochrane Central Register of Controlled Trials (CENTRAL). We will also search three Chinese databases (China Network Knowledge Infrastructure (CNKI), Wangfang Data and VIP Information) and five Korean databases (KoreaMed, the Research Information Service System (RISS), Oriental Medicine Advanced Searching Integrated System (OASIS), DBPIA and the Korean Studies Information Service System (KISS)).

### Searching other resources {#s2d2}

Ongoing studies will be sought in the meta-Register of Controlled Trials (mRCT; <http://www.controlled-trials.com/mrct>), Clinical trials.gov (<http://www.clinicaltrials.gov>) and the WHO International Clinical Trials Registry platform (ICTRP; <http://apps.who.int/trialsearch/>), all of which list ongoing trials. The bibliographic references of all of the included trials will be reviewed to identify other relevant studies. We will also contact the authors of the trial studies and experts in the field.

### Search strategy {#s2d3}

The strategies for searching The Cochrane Library, MEDLINE and EMBASE databases are presented in online supplementary appendix 1. These strategies will be modified for use with other databases.

Data collection and analysis {#s2e}
----------------------------

### Selection of studies {#s2e1}

Two of the review\'s authors (MJS and YHK) will independently screen the titles and abstracts of the searched studies, perform the study selection and record their decisions on a standard eligibility form. The arbitrator (MSL) will decide on the study selection when a consensus cannot be reached. The details of selection process will be shown in PRISMA flow diagram ([figure 1](#BMJOPEN2013004095F1){ref-type="fig"}).

![Study selection flow diagram.](bmjopen2013004095f01){#BMJOPEN2013004095F1}

### Data extraction and management {#s2e2}

Two of the authors (MJS and YHK) will independently extract the data using a standard data extraction form and resolve disagreements through discussion before analysis. When the reported data are insufficient or ambiguous, two of the authors (Y-EK and HWL) will contact the corresponding authors of the clinical trials by email or telephone to request additional information or clarification.

### Assessment of risk of bias in the included studies {#s2e3}

We will independently assess the risk of bias in the eligible studies according to the criteria described in the Cochrane Handbook V.5.1.0, which include random sequence generation, allocation concealment, blinding of participants and personnel, blinding of the outcome assessment, incomplete outcome data, selective reporting and other sources of bias.[@R28] The quality of the study will be classified as low, unclear or high risk of bias. If necessary, we will contact the authors of eligible trials for clarification. Any differences in opinion will be resolved by discussion or arbitration involving a third author.

### Measures of the treatment effect {#s2e4}

For continuous data, we will use the mean difference (MD) to measure the treatment effect at a 95% CI. We will convert other forms of data into MDs. In the case of outcome variables with different scales, we will use the standard MD with a 95% CI. For dichotomous data, we will present the treatment effects as a relative risk or risk difference with 95% CIs. Based on these results, we will calculate the associated numbers needed to treat.

### Unit of analysis issues {#s2e5}

Data from parallel-group studies will be included for meta-analysis. If there are cross-over trials, the first phase of the data will be adopted for analysis.

### Managing missing data {#s2e6}

We will request missing data from the original authors, whenever possible. If it is not possible to do this, we will only analyse the available data.

### Assessment of heterogeneity {#s2e7}

If a meta-analysis is possible, we will use the I^2^ statistic to quantify the inconsistencies among the included studies. An I^2^ value of \>50% will be considered indicative of substantial heterogeneity.[@R29] If heterogeneity is observed, we will conduct a subgroup analysis to explore its possible causes.[@R29]

### Assessment of reporting biases {#s2e8}

We will prepare funnel plots to assess the reporting biases if sufficient studies are available (at least 10 trials).[@R30] However, funnel plot asymmetry is not the same as publication bias; therefore, we will attempt to distinguish the different possible reasons for the asymmetry, such as small-study effects, poor methodological quality and the true heterogeneity of the included studies.[@R30] [@R31]

### Data synthesis {#s2e9}

Data synthesis for comparable trials with comparable outcomes will be performed using Review Manager (RevMan), V.5.2.6.

### Subgroup analysis and investigation of heterogeneity {#s2e10}

If the data are available, a predefined subgroup analysis will be conducted to assess the heterogeneity of different studies, including the following: Laterality of OME: bilateral OME versus unilateral OME;Duration of OME: any duration of OME versus persistent OME (lasting for more than 2 or 3 months);Duration of treatment;Type of herbal medicine;Type of control;Type of age group (participants aged over 18 years vs children aged 2 years or more vs children younger than 2 years).

### Sensitivity analysis {#s2e11}

Sensitivity analysis will principally be performed as follows: Sample size (eg, more or less than 40 participants in each group);Low risk of bias (eg, allocation concealment or the blinding of participants/assessors).

Discussion {#s3}
==========

As primary data collection will not be undertaken, no additional formal ethical assessment or informed consent is required. The systematic review will be published in a peer-reviewed journal. It will also be disseminated electronically and in print. The review will be updated, and a GRADE evaluation of the quality of evidence will be conducted to provide summaries of the future state of the evidence for the efficacy of interventions utilising herbal drugs on OME. The review may guide healthcare practices and policies regarding the oral administration of herbal medicines to treat OME.
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